DeHeng Advised Hidea Venture Capital on Leading

the A Series Investment of Hundreds of Millions of Yuan in Lexenpharm

2021-01-29

Recently Hidea (Tianjin) Investment Management Co., Ltd., as the lead investor, joined hands with TEDA Venture Capital Corporation Limited to complete the delivery of A Series capital increase of several hundred million yuan to Lexenpharm (Suzhou) Co., Ltd. This round of capital increase will accelerate Lexenpharm's research and development of new drugs and the construction of its international chemical plant in Suzhou.

Founded in 2000 with registered capital of RMB 1,873 million, TEDA Venture Capital, one of the first batch of specialized venture capital institutions in China, has grown into a comprehensive venture capital group. It has won many awards, including "Top 50 Venture Capitals in China," "Top 30 Healthcare Investment Institutions in China," "Best 50 Hard & Core Technology Investment Institutions in China," and "Top 100 in 20 Years of Venture Capital."

Partner Guo Weifeng of DeHeng's Beijing Office and his team have been providing legal services for Hidea Venture Capital and TEDA Venture Capital since their inception, and witnessed the growth of both clients and the industry. In this deal, the DeHeng team, led by partners Guo Weifeng and Tang Ruchuan, with primary support from lawyers Zhai Hao and Zhang Wendi, provided whole-process legal services including legal due diligence, VIE structure dismantling and new deal structure designing, transaction documents drafting and revising, business negotiations, and assistance in delivery, etc.